Jeffrey Weber, MD, PhD

Jeffrey Weber, MD, PhD, NYU Langone Medical Center's Laura and Isaac Perlmutter Cancer Center, discusses immunotherapies and BRAK/MEK inhibitors potentially being able to cure patients with melanoma. Weber says these treatments, such as ipilimumab plus nivolumab, or dabrafenib and trametinib, have seen marked improvements since 2009, and continue to become more important in the treatment paradigm of melanoma.

Videos

Weber says these treatments, such as ipilimumab plus nivolumab, or dabrafenib and trametinib, have seen marked improvements since 2009, and continue to become more important in the treatment paradigm of melanoma.

Dr. Jeffrey Weber on Potential Breakthrough "Cures" in Melanoma

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program, head of Experimental Therapeutics, NYU Langone Medical Center, discusses keys to targeted therapies for melanoma. These keys lie in BRAF and MEK inhibitors and combining those drugs with immunologic therapies.

Weber touches on several new combinations, adding that medical professionals have more treatment options than they ever have before. Weber said in order to prove superiority for these treatments over older therapies, several studies need to be conducted.

Jeffrey Weber, MD, PhD | Authors

Articles

Dr. Jeffrey Weber on Potential Breakthrough "Cures" in Melanoma

Dr. Jeffrey Weber on the Keys to Targeted Treatments